Jubilant Therapeutics
- Biotech or pharma, therapeutic R&D
Jubilant Therapeutics is focused on discovery and development of novel small molecules for the treatment of cancer and autoimmune disorders.
Company's lead assets
- JBI-802: Dual targeting CoREST inhibitor entered Phase I/II trials to treat Essential Thrombocythemia/Myeproliferative neoplasms (ET/MPN)
- JBI-778: Substrate competitive PRMT5i entered Phase I trials to treat mEGFR TKI resistant NSCLC, IDH+ High grade glioma (HGG) and Adenoid cystic carcinoma (ACC)
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}